La Jolla Pharmaceutical Company (LJPC)
(Delayed Data from NSDQ)
$8.26 USD
+0.22 (2.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.26 USD
+0.22 (2.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 13.33% and 58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -30% and 11.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 2.38% and 2.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -14.29% and 10.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
La Jolla Pharmaceutical (LJPC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 184.62% and 34.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will La Jolla Pharmaceutical (LJPC) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
La Jolla Pharma (LJPC) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.
How La Jolla (LJPC) Stock Stands Out in a Strong Industry
by Zacks Equity Research
La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will La Jolla Pharmaceutical (LJPC) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 5.10% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will La Jolla Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -0.93% and -18.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will La Jolla Pharmaceutical (LJPC) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?